Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Little Evidence Behind Bronchodilator Therapy for Cystic Fibrosis

26.10.2005


Little evidence exists to support the widespread use of bronchodilators to treat children and adults with cystic fibrosis, according to a new systematic review of published research.



“Recurrent wheeze and breathlessness are common in people with cystic fibrosis, and bronchodilators are commonly prescribed,” according to lead author Clare Halfhide, M.D., of the Royal Liverpool Children’s Hospital in England. “Despite their wide-scale and often long-term use, there is limited objective evidence about their efficacy in cystic fibrosis.”

The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.


Cystic fibrosis is a genetically inherited disease afflicting the lungs and the digestive system, the result of both parents passing on an abnormal gene. It is chronic, progressive and ultimately fatal.

Cystic fibrosis causes the exocrine glands, which produce sweat and mucus, to produce thick mucus that clogs the lungs, causing chronic respiratory difficulties. The mucus also obstructs pancreatic ducts, preventing digestive enzymes from reaching the intestines. Consequently, people with cystic fibrosis have difficulties breathing, absorbing nutrients and eliminating non-digested food.

The Cochrane review included 14 trials randomized controlled trials comprising 257 participants with cystic fibrosis.

Several trials compared inhaled bronchodilator drugs to placebo by looking at two common measures of lung function. Forced expiratory volume, or FEV1, represents the volume of air that can be forced out in one second after taking a deep breath. Peak expiratory flow rate represents how fast a person can exhale air.

Improvements occurred primarily in a subgroup of the cystic fibrosis patients studied. These patients were known to have bronchial hyper-responsiveness — increased response of the airway to certain stimuli. Bronchial hyper-responsiveness and responsiveness to bronchodilator drugs are markers for asthma and can be also tested for in people with cystic fibrosis.

The reviewers found the following:

-- Albuterol and terbutaline — drugs classified as short-acting beta2-agonists — increased FEV1 and peak expiratory flow rate for patients known to have bronchial hyper-responsiveness.

-- Serevent (salmeterol) — classified as a long-acting beta2-agonist — also improved lung function for participants known to have bronchial hyper-responsiveness.

-- Atrovent (ipratropium bromide) showed no consistent effects on lung function in the trials under review.

The reviewers found no published trials that included inhaler-delivered fenoterol, formoterol or tiotropium and wrote that use of those agents could not be supported.

The reviewers noted that the trials were too varied in design to allow for a pooling of data for a strict meta-analysis.

“[B]efore embarking on what might become lifelong bronchodilator therapy, bronchodilator responsiveness should be assessed by measuring lung function both before and after a test dose of salbutamol in a standardized way, looking for an increase in baseline FEV1 of at least 10 percent," the reviewers concluded.

John Colombo, M.D., professor and chief of the pediatric pulmonology section at the University of Nebraska Medical Center, said, “My bias is… that all CF [cystic fibrosis] patients deserve a trial of beta-agonist bronchodilator. This should be done in the PFT [pulmonary function test] laboratory, and, unless they develop significant adverse effects, short-acting beta-agonists should be considered as a trial for symptom relief, and possibly as an adjunct to airway clearance. A long-acting beta-agonist, of which salmeterol is the only one studied to date, should be considered for a period of home use with assessment for changes in symptoms, antibiotic requirement, and PFT course.”

About 30,000 people in the United States are affected with cystic fibrosis, and 2,500 to 3,000 babies are born annually with the condition. It most commonly occurs in Caucasians of Northern European heredity.

Clare Halfhide | EurekAlert!
Further information:
http://www.cfah.org
http://www.hbns.org

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

New risk factors for anxiety disorders

24.02.2017 | Life Sciences

MWC 2017: 5G Capital Berlin

24.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>